Limits...
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.

Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski CC - Cancer Sci. (2014)

Bottom Line: Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II).The cetuximab-based treatment cohort was analyzed for specificity assessment of CEA to predict the anti-vascular endothelial growth factor effect in mCRC.In an independent cohort of 129 patients treated with cetuximab-based therapy, no association of therapeutic response or PFS with CEA serum levels was found.

View Article: PubMed Central - PubMed

Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.

Show MeSH

Related in: MedlinePlus

Baseline serum carcinoembryonic antigen (CEA) levels and cetuximab-based therapies in patients with metastatic colorectal cancer. (a) Disease control was defined as complete remission, partial remission, or stable disease; CEA groups in the cetuximab population according baseline serum CEA (≤26.8 ng/mL vs >26.8 ng/mL). (b) Kaplan–Meier estimates for progression-free survival (PFS). Subgroups according to the baseline serum CEA levels, categorized at 26.8 ng/mL. (c) Kaplan–Meier estimates for overall survival (OS) by CEA group in cetuximab population (CEA ≤26.8 ng/mL vs CEA >26.8 ng/mL).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317865&req=5

fig04: Baseline serum carcinoembryonic antigen (CEA) levels and cetuximab-based therapies in patients with metastatic colorectal cancer. (a) Disease control was defined as complete remission, partial remission, or stable disease; CEA groups in the cetuximab population according baseline serum CEA (≤26.8 ng/mL vs >26.8 ng/mL). (b) Kaplan–Meier estimates for progression-free survival (PFS). Subgroups according to the baseline serum CEA levels, categorized at 26.8 ng/mL. (c) Kaplan–Meier estimates for overall survival (OS) by CEA group in cetuximab population (CEA ≤26.8 ng/mL vs CEA >26.8 ng/mL).

Mentions: Several reports have described that elevated CEA baseline levels might be prognostic.(21,22) Consistent with these results, the current study confirms a prognostic role of baseline CEA levels in mCRC patients treated with anti-VEGF-based therapy. In order to analyze whether baseline CEA serum levels simply reflect high tumor load, resulting in detrimental treatment outcome, a separate cohort of 129 patients who received cetuximab-based chemotherapy was analyzed. Thereby, baseline CEA serum levels (categorized at 26.8 ng/mL) were not associated with either DC (P = 0.281; Fig. 4a) or PFS (P = 0.221; Fig. 4b). However, as expected, CEA was prognostic as the OS in cetuximab-treated patients with higher CEA levels was decreased (median survival 23.4 months for group I vs 16.7 months for group II, P = 0.014; Fig. 4c).


Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.

Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski CC - Cancer Sci. (2014)

Baseline serum carcinoembryonic antigen (CEA) levels and cetuximab-based therapies in patients with metastatic colorectal cancer. (a) Disease control was defined as complete remission, partial remission, or stable disease; CEA groups in the cetuximab population according baseline serum CEA (≤26.8 ng/mL vs >26.8 ng/mL). (b) Kaplan–Meier estimates for progression-free survival (PFS). Subgroups according to the baseline serum CEA levels, categorized at 26.8 ng/mL. (c) Kaplan–Meier estimates for overall survival (OS) by CEA group in cetuximab population (CEA ≤26.8 ng/mL vs CEA >26.8 ng/mL).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317865&req=5

fig04: Baseline serum carcinoembryonic antigen (CEA) levels and cetuximab-based therapies in patients with metastatic colorectal cancer. (a) Disease control was defined as complete remission, partial remission, or stable disease; CEA groups in the cetuximab population according baseline serum CEA (≤26.8 ng/mL vs >26.8 ng/mL). (b) Kaplan–Meier estimates for progression-free survival (PFS). Subgroups according to the baseline serum CEA levels, categorized at 26.8 ng/mL. (c) Kaplan–Meier estimates for overall survival (OS) by CEA group in cetuximab population (CEA ≤26.8 ng/mL vs CEA >26.8 ng/mL).
Mentions: Several reports have described that elevated CEA baseline levels might be prognostic.(21,22) Consistent with these results, the current study confirms a prognostic role of baseline CEA levels in mCRC patients treated with anti-VEGF-based therapy. In order to analyze whether baseline CEA serum levels simply reflect high tumor load, resulting in detrimental treatment outcome, a separate cohort of 129 patients who received cetuximab-based chemotherapy was analyzed. Thereby, baseline CEA serum levels (categorized at 26.8 ng/mL) were not associated with either DC (P = 0.281; Fig. 4a) or PFS (P = 0.221; Fig. 4b). However, as expected, CEA was prognostic as the OS in cetuximab-treated patients with higher CEA levels was decreased (median survival 23.4 months for group I vs 16.7 months for group II, P = 0.014; Fig. 4c).

Bottom Line: Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II).The cetuximab-based treatment cohort was analyzed for specificity assessment of CEA to predict the anti-vascular endothelial growth factor effect in mCRC.In an independent cohort of 129 patients treated with cetuximab-based therapy, no association of therapeutic response or PFS with CEA serum levels was found.

View Article: PubMed Central - PubMed

Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.

Show MeSH
Related in: MedlinePlus